Blog
A Continued Partnership
In partnership since 2018, South Sound CARE Foundation and MultiCare Institute for Research and Innovation (MIRI) took an additional step in 2022 to extend trial access to South Sound cancer patients.
Our CARE Community: Meet Study Director Kimberly Burton, PhD
Our CARE community makes all the difference. Get to know CARE’s Study Director Kimberly Burton, PhD.
Meet CARE Supporters Greg & Kaycie Hersey
The Hersey family is committed to making the South Sound a better place for generations to come. Read their story and learn why CARE is important to Greg and Kaycie.
What Everyone Knows about Cancer: And What Cancer has Taught Me
Stretched physically, emotionally, socially and spiritually since her breast cancer diagnosis in 2016, Julie processes through her writing. We asked her what she wanted others to know about participating in a clinical trial...this is what she shared.
Understanding The Tumor Board
After watching countless patients walk this extremely difficult path, in 2013, Dr. Tony Blau, Dr. Sibel Blau, and Dr. Frank Senecal decided to design a study to provide hope for patients fighting metastatic triple-negative breast cancer.
Happy Holidays From The South Sound CARE Foundation
A holiday letter from Dr. Frank Senecal.
Compassionate Use Has Given This Family Hope
You help stories like this possible. Meet the Zubin family.
Introducing New Technology For Compassionate Use Patients In The South Sound
For a cancer patient who has exhausted all lines of traditional treatment and conventional trials, Compassionate Use is frequently their last resort. Compassionate Use are “trials” in which the FDA and pharmaceutical companies work together to bring a specific treatment to a patient—or a group of patients—which otherwise would not be available. The process of acquiring the medication for a Compassionate Use trial can be very tedious and is typically estimated at nearly 120 hours per Compassionate Use request.
New York Times Article Features ITOMIC Triple Negative Breast Cancer Study
For a cancer patient who has exhausted all lines of traditional treatment and conventional trials, Compassionate Use is frequently their last resort. Compassionate Use are “trials” in which the FDA and pharmaceutical companies work together to bring a specific treatment to a patient—or a group of patients—which otherwise would not be available. The process of acquiring the medication for a Compassionate Use trial can be very tedious and is typically estimated at nearly 120 hours per Compassionate Use request.